sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
guangdong
provinc
china
infect
individu
result
mortal
rate
rota
et
al
later
novel
cov
middl
east
respiratori
syndrom
coronaviru
merscov
isol
sputum
man
saudi
arabia
perl
et
al
notabl
merscov
recent
reemerg
republ
korea
kill
confirm
case
korea
center
diseas
control
prevent
therefor
sarscov
still
carri
potenti
resurg
effort
made
prevent
recurr
epidem
current
effect
antivir
strategi
control
sarscov
infect
lack
vaccin
still
regard
major
approach
prevent
sar
relat
diseas
gener
virusspecif
antibodi
play
import
role
control
viral
infect
howev
presenc
specif
antibodi
benefici
infect
case
virus
includ
flavivirus
cov
retrovirus
de
alwi
et
al
jolli
weiss
takano
et
al
vaccineinduc
enhanc
suscept
sarscov
document
one
studi
show
antibodi
sarscov
spike
protein
potenti
infect
monocyt
lymphoid
cell
line
express
viru
receptor
report
antibodydepend
enhanc
ade
mediat
vaccineinduc
infect
aggrav
yip
et
al
previous
report
inactiv
sarscov
vaccin
effect
elicit
neutral
protect
antibodi
respons
rhesu
macaqu
luo
et
al
zhou
et
al
thu
ensur
safeti
vaccin
clinic
use
present
studi
examin
whether
vaccin
trigger
ade
demonstr
higher
concentr
antisera
sarscov
neutral
sarscov
infect
highli
dilut
antisera
significantli
increas
sarscov
infect
trigger
ade
effect
moreov
low
level
neutral
antibodi
consist
context
vaccin
gener
popul
find
low
neutral
antibodi
stage
challeng
promis
therefor
determin
ade
inactiv
sarscov
vaccin
first
establish
model
low
level
neutral
antibodi
sixteen
adult
chines
rhesu
macaqu
male
femal
kg
individu
hous
isol
cage
anim
biosafeti
level
absl
iii
laboratori
wuhan
univers
wuhan
china
monkey
random
group
monkey
immun
group
monkey
viru
control
group
monkey
neg
control
group
male
femal
monkey
equal
assign
group
immun
intramuscularli
lg
betapropiolactoneinactiv
whole
sarscov
vaccin
pb
control
boost
day
blood
collect
week
postimmun
neutral
antibodi
test
plaqu
reduct
neutral
test
follow
immun
anim
monitor
daili
clinic
sign
chang
activ
rectal
temperatur
appetit
frequenc
defec
stool
consist
hematolog
examin
test
sysmex
kobe
japan
serum
alanin
aminotransferas
alt
aspart
aminotranferas
ast
total
bilirubin
tbil
total
protein
tp
urea
creatinin
crea
alkalin
phosphatas
alp
level
detect
semiautomat
biochem
analyz
rayto
corpor
shenzhen
evalu
liver
kidney
function
observ
clinic
sign
anim
normal
data
shown
system
complic
observ
none
monkey
show
skin
rash
vaccin
inject
site
hematolog
assay
result
normal
rang
supplementari
tabl
elev
biochem
indic
observ
immun
supplementari
tabl
shown
fig
neutral
antibodi
titer
monkey
week
first
immun
consist
studi
requir
woo
et
al
result
suggest
inactiv
vaccin
safe
immun
rhesu
macaqu
could
use
model
test
ade
candid
vaccin
next
use
aboveestablish
model
evalu
correl
vaccin
infect
sever
week
postimmun
immun
monkey
viru
control
monkey
intratrach
challeng
sarscov
tissu
cultur
infecti
dose
tcid
per
anim
four
neg
control
monkey
challeng
pb
control
blood
nasopharyng
secret
collect
day
postchalleng
virolog
evalu
anim
provid
full
support
care
human
kill
day
postinfect
lung
tissu
fix
formalin
embed
section
stain
hematoxylin
eosin
patholog
observ
homogen
lung
lobe
prepar
rtpcr
assay
sarscov
viru
isol
follow
viru
challeng
remark
rectal
temperatur
chang
note
vaccin
fig
low
level
neutral
antibodi
induc
inactiv
vaccin
sarscov
trigger
ade
follow
challeng
rhesu
macaqu
immun
intramuscularli
lg
betapropiolactoneinactiv
whole
sarscov
vaccin
pb
control
boost
day
blood
collect
week
postimmun
titer
express
reciproc
dilut
plaqu
reduc
complet
viruswel
data
present
mean
se
group
b
day
postinfect
surviv
monkey
three
group
euthan
necropsi
lung
collect
fix
use
formaldehyd
section
subject
hematoxylin
eosin
stain
magnif
arrow
refer
widen
alveolar
septa
infiltr
inflammatori
cell
c
nasopharyng
swab
collect
day
postchalleng
presenc
sarscov
polymeras
gene
swab
confirm
lane
immun
group
lane
viru
control
group
lane
swab
neg
control
group
molecular
size
marker
pc
purifi
viru
posit
control
nc
without
cdna
templat
viru
titer
sera
monkey
whose
sampl
show
posit
result
viru
isol
detect
day
postchalleng
tcid
valu
titer
express
directli
calcul
number
immun
anim
clinic
symptom
cough
lethargi
rash
observ
vaccin
anim
likewis
normal
bodi
weight
gain
observ
vaccin
anim
infect
noninfect
monkey
remain
aliv
sacrif
shown
fig
histopatholog
observ
indic
monkey
viru
control
group
obviou
interstiti
pneumonia
includ
thicken
alveolar
wall
infiltr
mononuclear
cell
lymphocyt
interstiti
pneumonia
also
observ
immun
group
fewer
patholog
chang
observ
accord
degre
histopatholog
chang
among
viru
control
group
one
monkey
present
sever
interstiti
pneumonia
two
monkey
display
moder
interstiti
pneumonia
one
monkey
slight
interstiti
pneumonia
meanwhil
immun
group
four
monkey
develop
moder
interstiti
pneumonia
four
monkey
mild
interstiti
pneumonia
infecti
viru
isol
variou
sampl
collect
monkey
differ
time
point
postchalleng
filter
nasopharyng
wash
serum
lung
tissu
homogen
inocul
onto
cell
monolay
plate
costar
corn
inc
usa
cultur
plate
observ
day
blindli
passag
two
time
sarscovspecif
cytopathogen
effect
cpe
exhibit
posit
rate
viru
isol
nasopharyng
swab
sera
immun
monkey
lower
viru
control
gener
howev
posit
rate
viru
isol
consist
among
lung
specimen
shown
tabl
rtpcr
use
test
presenc
polymeras
gene
sarscov
nasopharyng
secret
sera
lung
monkey
three
group
forward
revers
primer
caccgtttctacaggtta
aaatgtttacgcaggtaacg
respect
rate
viral
rna
detect
nasopharyng
secret
sera
taken
immun
group
lower
viru
control
group
day
postchalleng
lung
monkey
immun
group
viru
control
group
posit
day
postchalleng
respect
posit
rate
consist
correl
viru
isol
result
tabl
nasopharyng
secret
obtain
immun
group
viru
control
group
day
postchalleng
posit
sarscov
rna
fig
viral
titer
monkey
sera
posit
viru
determin
day
postchalleng
viru
titer
calcul
reedmuench
formula
express
tcid
ml
reed
muench
shown
fig
although
viru
titer
immun
group
slightli
lower
viru
control
group
univers
differ
statist
signific
altogeth
result
indic
sarscov
replic
immun
group
enhanc
sever
sarscov
vaccin
develop
use
differ
vaccin
platform
includ
whole
inactiv
dna
subunit
vector
vaccin
enjuan
et
al
robert
et
al
immunogen
efficaci
experiment
vaccin
evalu
anim
model
mice
ferret
hamster
nonhuman
primat
robert
et
al
monkey
wide
studi
anim
model
sar
research
similar
anoth
studi
qin
et
al
inactiv
sar
vaccin
monkey
previou
studi
inactiv
sarscov
vaccin
elicit
robust
serumneutr
antibodi
respons
rhesu
macaqu
provid
protect
challeng
viru
nevertheless
least
one
report
indic
sarscov
vaccin
candid
base
recombin
fulllength
sarscov
spike
protein
trigger
infect
human
b
cell
line
vitro
despit
elicit
neutral
protect
immun
respons
rodent
kam
et
al
addit
least
two
studi
shown
antisarscovspik
immun
serum
potenti
infect
tabl
detect
sarscov
variou
specimen
three
group
differ
day
postchalleng
nasopharyng
swab
sera
lung
day
day
day
day
day
day
day
day
day
day
day
immun
cell
line
sarscov
antibodymedi
ade
jaum
et
al
wang
et
al
meanwhil
anoth
research
group
perform
ade
assay
use
sera
patient
posit
sarscov
research
data
show
treatment
human
promonocyt
dilut
antisera
collect
patient
posit
sarscov
result
increas
viru
infect
cytopath
effect
therefor
present
studi
although
clinic
histopatholog
observ
viral
assay
indic
viru
infect
enhanc
believ
vitro
ade
assay
also
perform
examin
whether
immun
sera
induc
inactiv
vaccin
mediat
ade
cell
line
cell
monkey
peripher
blood
mononuclear
cell
moreov
need
investig
molecular
mechan
respons
antibodymedi
infect
vitro
conclus
clinic
virolog
patholog
find
present
studi
reveal
exacerb
infect
rhesu
macaqu
immun
inactiv
sarscov
vaccin
follow
challeng
sarscov
therefor
result
preliminarili
indic
low
level
antibodi
induc
inactiv
sarscov
vaccin
may
induc
ade
rhesu
macaqu
vaccin
could
good
candid
clinic
trial
